Abcam, ab248155, Anti-GAMT antibody [EPR6925] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal GAMT antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR6925,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab248155 is the carrier-free version of
ab126736
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Guanidinoacetate N-methyltransferase commonly known as GAMT catalyzes the conversion of guanidinoacetate to creatine through methylation. The enzyme has a molecular mass of approximately 24 kDa. GAMT is expressed in various body tissues with high levels observed in the liver and kidney. The enzyme plays an important role in the synthesis of creatine an important molecule for energy storage and supply in muscle tissues.
Biological function summary
GAMT participates in the final step of creatine biosynthesis. This enzyme acts independently rather than forming part of a larger complex. In the cells creatine serves as an energy buffer predominantly involved in tissues with high and fluctuating energy demands such as muscles and the brain. GAMT's activity ensures a steady supply of creatine which supports cellular energy homeostasis.
Pathways
GAMT plays a significant role in the creatine biosynthesis pathway. This pathway is vital for maintaining the energy balance in cells especially those with a high-energy requirement. GAMT directly interacts with guanidinoacetate as a substrate with S-adenosylmethionine serving as the methyl group donor. Additionally GAMT is connected to the arginine and proline metabolism pathway alongside other enzymes such as arginine-glycine amidinotransferase (AGAT) which acts earlier in the creatine biosynthetic pathway.
Mutations or deficiencies in GAMT associate with disorders such as GAMT deficiency which leads to creatine deficiency syndromes. This condition typically results in neurological impairments including developmental delays and cognitive dysfunctions. The disorder also relates to disrupted creatine production in which AGAT and other enzymes within the creatine biosynthetic pathway may contribute to similar phenotypic outcomes. Research into these connections aids in understanding the broader implications of GAMT dysfunction.